Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
- Yield10 granted a global license to Vision Bioenergy for Camelina products.
- Recent regulatory milestones support the commercial ramp-up of engineered Camelina varieties.
- The company ended 2023 with $1.1 million in cash and investments.
- Net loss for the year was $14.5 million.
- Yield10 plans to focus on executing the development program for omega-3 Camelina in 2024.
- Net loss increased from $13.6 million in 2022 to $14.5 million in 2023.
- The company ended 2023 with a decreased cash balance compared to 2022.
- Research grant revenue decreased from $0.5 million in 2022 to $0.1 million in 2023.
Insights
The granting of a global commercial license to Vision Bioenergy by Yield10 Bioscience for the production of Camelina feedstock oil for biofuels represents a strategic move within the agricultural bioscience and renewable energy sectors. This development taps into the increasing demand for sustainable biofuels, particularly in the aviation, maritime and heavy-duty transport industries. The biofuel market is poised for growth due to global decarbonization efforts and the transition towards renewable energy sources. The license agreement, which includes $3 million in cash payments to Yield10, can potentially provide a new revenue stream and strengthen the company's financial position in the medium to long term.
Additionally, Yield10's focus on commercializing omega-3 Camelina oil for aquafeed and nutritional markets aligns with the rising consumer demand for omega-3 fatty acids, recognized for their health benefits. The regulatory clearance for planting omega-3 Camelina in Canada and the anticipated approval in Chile could accelerate market penetration and revenue generation. However, the company's financial health, as evidenced by a decrease in unrestricted cash and investments from $4.3 million to $1.1 million year-over-year, raises concerns about its ability to sustain operations and investments without additional funding sources. Investors should monitor Yield10's execution of its development and commercialization plans, as delays or failures could impact the company's financial viability and stock performance.
Yield10 Bioscience's financial results for the year ended December 31, 2023, reveal a reduction in cash usage for operating activities from $11.4 million to $10.1 million, indicating a more disciplined approach to cash flow management. This is a positive signal for cost-conscious investors, as the company appears to be streamlining operations and delaying payments to conserve cash. However, the net loss of $14.5 million for the full year 2023, compared to a net loss of $13.6 million in 2022, reflects ongoing financial challenges. The reported increase in research and development expenses due to higher crop trial and seed production costs is noteworthy because it suggests investment in product development, which could lead to future revenue growth if successful.
The $3.0 million cash proceeds from the commercial license agreement with Vision Bioenergy and the $1.2 million raised from a warrant inducement transaction in early 2024 provide a temporary financial cushion. Still, the company's ability to achieve profitability is uncertain and depends on the successful commercialization of its Camelina products. The reduction in grant revenue from $0.5 million to $0.1 million also indicates a potential need for Yield10 to diversify its funding sources to mitigate the impact of fluctuating grant contributions on its financial stability.
Yield10 Bioscience's advancements in agricultural biotechnology, particularly the development of Camelina varieties with enhanced traits such as herbicide tolerance (HT) and increased omega-3 oil production, are significant. These innovations could improve crop performance, yield and value, which are critical factors for widespread adoption among growers. The regulatory achievements, including the positive response from USDA-APHIS for the proprietary elite Camelina varieties and the determination by the CFIA that E3902 Camelina is not a Plant with Novel Trait (PNT), reduce barriers to market entry and facilitate the path to commercial scale planting.
However, the success of these biotechnological advancements hinges on Yield10's ability to navigate the complex regulatory landscape and secure partnerships for commercialization. The strategic focus on the aquafeed and nutritional markets for omega-3 products is well-founded, given the established health benefits and market demand for these fatty acids. The integration of HT and omega-3 traits to produce new Camelina varieties could further enhance the crop's marketability and appeal to a broader range of end-users. The company's efforts to establish a closed-loop production system, from seed supply to oil and meal sale, demonstrate a comprehensive approach to value chain management that could lead to increased efficiency and profitability in the long run.
-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market
-Advanced regulatory and seed scale-up program for omega-3 Camelina
-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada
-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update
WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
"In 2023 we successfully executed our plan and achieved several key milestones that position Yield10 to build a sustainable products business based on engineered Camelina," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "Our crop innovations are intended to support grower adoption of the crop and enable commercial-scale planting to produce Camelina oil and meal products targeting significant market opportunities.
"We believe Camelina represents a game changer for producing omega-3 oil and meal products. In early 2024, we made the strategic decision to focus our resources on the commercialization of Camelina products targeting the aquafeed and nutritional markets for omega-3 fatty acids. In the year ahead, we plan to focus on executing our development program for omega-3 Camelina, building seed inventory in anticipation of commercial scale planting, obtaining regulatory approval to sell omega-3 oil for aquafeed in Chile, and engaging with potential commercial partners to enable future commercial sale of omega-3 oil and meal in target markets. If all goes according to plan, we estimate that our omega-3 products could begin producing revenue as early as 2025.
“We also recently achieved significant regulatory milestones supporting our commercial plans. USDA-APHIS completed review of our herbicide tolerance (“HT”) and omega-3 traits enabling us to plan for the commercial ramp-up of engineered Camelina varieties containing these traits in the U.S. We believe herbicide tolerance will be a significant factor in driving the adoption of Camelina. Our team is creating a portfolio of Camelina varieties incorporating these traits and others to improve the performance and value of the crop.
"In early 2024, Yield10 granted to Vision Bioenergy Oilseeds (“VISION”) a global license to certain proprietary varieties of Camelina for the production of feedstock oil for biofuels. This agreement is intended to empower farmers to capitalize on the growing biofuel market while advancing the decarbonization goals of aviation, maritime, and heavy-duty transport industries. Yield10 plans to work with biofuel players to support the production of Camelina feedstock oil.
“In 2023 we demonstrated closed-loop production of Camelina as we supplied our seed to growers under contract and arranged the offtake and sale of the grain to a biofuel refiner. We intend to continue to build relationships across the value chain to support increasing scale of Camelina production and sale of oil and meal into target markets.
"In the coming months, we expect to execute on our commercial and regulatory plan to produce omega-3 oil and meal products in Camelina, to combine our HT and omega-3 traits to produce new Camelina varieties, and to continue to support grower adoption of Camelina," said Dr. Peoples.
Recent Accomplishments
Recent progress by Yield10 is underscored by the key milestones achieved during 2023 and is setting the direction for the Company’s business strategy in 2024, including:
- Yield10 planted omega-3 (EPA) Camelina at the 50 acre-scale in Chile to produce oil for use in business development activities. The crop was harvested in early 2024.
- In March of 2024, USDA-APHIS provided a positive response to the Company's announced filings for two requests for a Regulatory Status Review (RSR) with USDA-APHIS's Biotechnology Regulatory Services (BRS) under the SECURE Rule for proprietary elite Camelina varieties containing genes enabling the plant to produce the EPA and EPA+DHA components of omega-3 oil. Yield10 plans to conduct seed scale-up activities with omega-3 Camelina in 2024. Omega-3 fatty acids are used in aquafeed as well as for nutraceutical and pharmaceutical products.
- In November of 2023, USDA-APHIS determined that Yield10’s glufosinate tolerant Camelina as well as its stacked herbicide tolerant Camelina may be planted and bred in the United States in response to two Requests for Regulatory Status Review (“RSRs”) packages submitted by Yield10. An application to add Camelina to a glufosinate label is pending with the U.S. Environmental Protection Agency.
- In early 2024, Yield10 granted to Vision Bioenergy Oilseeds a global license to certain proprietary varieties of Camelina for the production of feedstock oil for biofuels. Commercial production of Camelina is currently ramping up in North America as a source of ultra-low carbon feedstock oil for the biofuel industry. In consideration for the license and completion of certain deliverables, Vision will make cash payments to Yield10 totaling
$3 million .
- We recently reported encouraging results from the first field testing of our winter HT and Stacked HT Camelina varieties. We expect to harvest the winter field test plantings later this year and conduct an evaluation of seed yield, oil content, herbicide tolerance and overall agronomy.
- In early 2024, the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) reviewed information on the Company’s E3902 Camelina sativa (“Camelina”) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. Yield10’s E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by five percent.
- In 2023, Yield10 successfully demonstrated the supply chain from seed to growers contracts to oil and meal offtake to customers. In the fall of 2023, Yield10 signed growers contracts representing approximately 1,200 acres of winter Camelina production which is expected to be harvested in the third quarter of 2024.
FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL OVERVIEW
Cash Position
Yield10 is managed with an emphasis on cash flow and deploys its financial resources in a disciplined manner to achieve its key strategic objectives.
Yield10 used
Operating Results
Research grant revenue for the year ended December 31, 2023 was
Yield10 reported a net loss of
During the fourth quarter of 2023, research and development expense increased by
Conference Call Information
Yield10 Bioscience management will host a conference call today at 4:30 p.m. (ET) to discuss the fourth quarter and full year 2023 results. The Company also will provide a corporate update and answer questions from the investor community. A live webcast of the call with slides can be accessed through the Company's website at www.yield10bio.com in the investor relations events section. To participate in the call, dial toll-free 877-709-8150 or 201-689-8354 (international). Reference Event ID:13745439. The webcast will be archived on the Company's website in the investor relations events section.
About Yield10 Bioscience
Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa ("Camelina") as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics. Subject to the availability of sufficient financial resources to continue operations, our commercial plan is based on establishing a grain contracting business leveraging our proprietary elite Camelina seed varieties, focusing on the growing demand for low-carbon intensity feedstock oil for biofuels and omega-3 oils for nutritional applications. Yield10 is headquartered in Woburn, MA and has a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon, Canada.
For more information about the Company, please visit www.yield10bio.com, or follow the Company on X (formerly Twitter), Facebook and LinkedIn.
(YTEN-E)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, expectations regarding Yield10’s cash position, cash forecasts and runway, expectations related to research and development and commercialization activities, intellectual property, the expected regulatory path for traits, reproducibility of data from field tests, the timing of completion of additional greenhouse and field test studies, the outcomes of its 2024 seed production activities, 2024 spring field tests, 2023-2024 winter field tests, Camelina planting under growers contracts and seed scale-up activities, the signing of research licenses and collaborations, including whether the objectives of those collaborations will be met, whether the Company will be able to generate proof points for traits in development and advance business discussions around its Camelina business plan, the geopolitical uncertainty caused by the conflict between Ukraine and Russia, and value creation as well as the overall progress of Yield10, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the Company’s ability to secure adequate funding in the near term to continue operations and to remain listed on the Nasdaq Stock Market, as to which no assurance can be given, as well as the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.
Contacts:
Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
(FINANCIAL TABLES FOLLOW)
| YIELD10 BIOSCIENCE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED (In thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenue: | |||||||||||||||
| Grant revenue | $ | — | $ | 87 | $ | 60 | $ | 450 | |||||||
| Total revenue | — | 87 | 60 | 450 | |||||||||||
| Expenses: | |||||||||||||||
| Research and development | 1,960 | 1,888 | 8,323 | 7,750 | |||||||||||
| General and administrative | 1,287 | 1,403 | 6,154 | 6,151 | |||||||||||
| Total expenses | 3,247 | 3,291 | 14,477 | 13,901 | |||||||||||
| Loss from operations | (3,247 | ) | (3,204 | ) | (14,417 | ) | (13,451 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Other income (expense), net | (19 | ) | 30 | (38 | ) | 41 | |||||||||
| Total other income (expense) | (19 | ) | 30 | (38 | ) | 41 | |||||||||
| Loss from operations before income taxes | (3,266 | ) | (3,174 | ) | (14,455 | ) | (13,410 | ) | |||||||
| Income tax provision | — | (129 | ) | — | (156 | ) | |||||||||
| Net loss | $ | (3,266 | ) | $ | (3,303 | ) | $ | (14,455 | ) | $ | (13,566 | ) | |||
| Basic and diluted net loss per share | $ | (0.27 | ) | $ | (0.67 | ) | $ | (1.82 | ) | $ | (2.76 | ) | |||
| Number of shares used in per share calculations: | |||||||||||||||
| Basic and diluted | 11,980,392 | 4,943,727 | 7,946,281 | 4,914,565 | |||||||||||
| YIELD10 BIOSCIENCE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED (In thousands, except share and per share amounts) | |||||||
| December 31, 2023 | December 31, 2022 | ||||||
| Assets | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 1,068 | $ | 2,356 | |||
| Short-term investments | — | 1,991 | |||||
| Unbilled receivables | — | 30 | |||||
| Prepaid expenses and other current assets | 332 | 641 | |||||
| Total current assets | 1,400 | 5,018 | |||||
| Restricted cash | 264 | 264 | |||||
| Property and equipment, net | 548 | 775 | |||||
| Right-of-use assets, net | 1,653 | 1,961 | |||||
| Other assets | 42 | 67 | |||||
| Total assets | 3,907 | $ | 8,085 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | |||||||
| Current Liabilities: | |||||||
| Accounts payable | 1,202 | $ | 109 | ||||
| Accrued expenses | 2,010 | 926 | |||||
| Current portion of lease liabilities | 669 | 575 | |||||
| Convertible note payable, net of issuance costs | 984 | — | |||||
| Total current liabilities | 4,865 | 1,610 | |||||
| Lease liabilities, net of current portion | 1,525 | 2,075 | |||||
| Total liabilities | 6,390 | 3,685 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ Equity (Deficit): | |||||||
| Preferred stock ( | — | — | |||||
| Common stock ( | 120 | 49 | |||||
| Additional paid-in capital | 411,814 | 404,277 | |||||
| Accumulated other comprehensive loss | (265 | ) | (229 | ) | |||
| Accumulated deficit | (414,152 | ) | (399,697 | ) | |||
| Total stockholders’ equity (deficit) | (2,483 | ) | 4,400 | ||||
| Total liabilities and stockholders’ equity (deficit) | 3,907 | $ | 8,085 | ||||
| YIELD10 BIOSCIENCE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED (In thousands) | |||||||
| Twelve Months Ended December 31, | |||||||
| 2023 | 2022 | ||||||
| Cash flows from operating activities | |||||||
| Net loss | $ | (14,455 | ) | $ | (13,566 | ) | |
| Adjustments to reconcile net loss to cash used in operating activities: | |||||||
| Depreciation and amortization | 290 | 263 | |||||
| Charge for 401(k) company common stock match | 108 | 133 | |||||
| Stock-based compensation | 1,592 | 1,903 | |||||
| Non-cash lease expense | 308 | 393 | |||||
| Deferred income tax provision | — | 165 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | — | 164 | |||||
| Unbilled receivables | 30 | 4 | |||||
| Prepaid expenses and other assets | 345 | (160 | ) | ||||
| Accounts payable | 1,093 | 26 | |||||
| Accrued expenses | 1,077 | (209 | ) | ||||
| Lease liabilities | (456 | ) | (520 | ) | |||
| Net cash used in operating activities | (10,068 | ) | (11,404 | ) | |||
| Cash flows from investing activities | |||||||
| Purchase of property and equipment | (46 | ) | (154 | ) | |||
| Purchase of investments | — | (2,445 | ) | ||||
| Proceeds from the maturity of short-term investments | 1,991 | 11,121 | |||||
| Net cash provided by investing activities | 1,945 | 8,522 | |||||
| Cash flows from financing activities | |||||||
| Proceeds from issuance of common stock and warrants in equity offerings, net of issuance costs | 5,842 | — | |||||
| Proceeds from At-the-Market offering, net of issuance costs | 103 | — | |||||
| Proceeds for convertible debt note | 967 | — | |||||
| Taxes paid on employees' behalf related to vesting of stock awards | — | (37 | ) | ||||
| Net cash provided by (used in) financing activities | 6,912 | (37 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (36 | ) | (54 | ) | |||
| Net increase (decrease) in cash, cash equivalents and restricted cash | (1,288 | ) | (2,973 | ) | |||
| Cash, cash equivalents and restricted cash at beginning of period | 2,620 | 5,593 | |||||
| Cash, cash equivalents and restricted cash at end of period | $ | 1,332 | $ | 2,620 | |||
| Supplemental Cash Flow Disclosure: | |||||||
| Interest paid | $ | 68 | $ | 10 | |||
| Right-of-use assets acquired in exchange for lease liabilities | $ | 138 | $ | — | |||
FAQ
What is the ticker symbol for Yield10 Bioscience?
What did Yield10 Bioscience achieve in 2023?
What did Yield10 Bioscience focus on in early 2024?
What was the net loss for Yield10 Bioscience in 2023?
What was the cash balance for Yield10 Bioscience at the end of 2023?
